Mayo Clinic’s menopause-related services cover more than a request for hormone treatment. Sexual-health concerns, symptoms after cancer treatment and other midlife questions can lead to different assessments. A capsule name alone cannot tell a reader which of those consultations would be relevant.
This review, dated September 29, 2026, considers Mayo’s Minnesota menopause service and its Florida women’s health specialty center. Both provide actual clinical care. Neither reviewed page confirms a specific oral progesterone product, an included pharmacy service or the outcome of an individual appointment.
In this article
The Minnesota service has several distinct purposes
Mayo’s Rochester service brings together menopause, women’s sexual health and cancer survivorship concerns. Its program overview describes an assessment that may involve education, testing, referrals and treatment recommendations. The team can include professionals with different responsibilities, such as nursing, sexual-health support and physical therapy. That is a wider clinical setting than a capsule purchasing page.
The first distinction is therefore the problem the visit will address. The Cleveland Clinic review examines another broad service but a different visit format. Comparing the consultation’s structure is legitimate. Inferring that the two institutions use the same oral product, or that every concern leads to hormone prescribing, would go beyond either public description.
Florida is a separate service, not a duplicate checkout
The Florida Women’s Health Specialty Center describes care for menopausal and hormonal concerns, including menopause associated with surgery or cancer treatment. It also addresses sexual health. That center’s overview is direct evidence of a service in Florida, but it does not provide a medicine menu or explain a unified national prescription pathway.
A patient’s eventual appointment, professional team and access requirements would have to be confirmed for the chosen location. The existence of two Mayo programs does not establish remote eligibility elsewhere. It also does not mean that recommendations made in different clinical circumstances are interchangeable. Location and consultation purpose remain useful facts even when the exact formulation is still unknown.
A capsule label cannot answer every menopause question
Prometrium’s patient information identifies specific uses for oral progesterone, including a role with estrogen after menopause for a woman with a uterus. It also discusses secondary amenorrhea. Those are defined product uses, not a statement that the capsule treats every concern listed by a menopause or sexual-health center. The current label should remain narrower than Mayo’s overall service description.
The purpose guide helps separate the medicine’s intended role from the reason someone first seeks care. A clinician would need to explain how a proposed prescription relates to that person’s assessment. This review does not infer an indication from age, a symptom list, the presence of a uterus or a preferred brand name.
“Bioidentical” leaves formulation questions unanswered
Mayo’s service information discusses hormonal and nonhormonal approaches, including bioidentical hormone therapy. That terminology alone does not identify an approved oral capsule or a compounded preparation. The Mayo program page does not establish that a particular patient would receive either. Product approval, route and ingredients need their own evidence.
FDA explains that compounded medicines are not FDA-approved, even though they can meet particular medical needs. That regulatory distinction should not be turned into an allegation about Mayo’s prescribing. It is a question to resolve when an actual product is proposed. The Prometrium product review illustrates the more precise level of identification required for a capsule-specific discussion.
The ingredient record belongs beside the proposed medicine
The documented Prometrium formulation includes peanut oil, with a corresponding peanut-allergy contraindication. Its inactive-ingredient information is relevant if that is the product under consideration; it cannot describe every possible preparation a clinician might discuss. The label’s ingredient information demonstrates why a familiar active-ingredient name is not enough to identify a capsule completely.
The guide to capsule excipients focuses on that gap. Clinical allergy assessment and verification of the dispensed formulation have related but different roles. Mayo’s public program pages cannot complete either task for an individual. Nor can a previous prescription or another person’s capsule establish the ingredients of a newly proposed medicine.
Coordination should not be confused with an included package
Mayo describes a team capable of arranging additional expertise when appropriate. It does not publish a complete progesterone-specific price, included test list or recurring treatment package in the reviewed pages. The Minnesota overview therefore supports the availability of consultation and recommendations, while leaving the financial and practical scope of an individual encounter unresolved.
The Johns Hopkins review considers another multidisciplinary program, with an explicit referral route. Such comparisons can clarify organizational questions: who receives the request, which appointment is being arranged, and whether another consultation has separate responsibilities. They cannot establish that coordination includes every future visit, prescription cost or insurance authorization.
The written explanation matters after the consultation
A useful explanation of a proposed medicine would distinguish its purpose, actual product information and the contact responsible for later questions. That is particularly important when a broad service involves more than one professional. Mayo’s Florida center description confirms varied areas of care; it does not specify a universal capsule follow-up schedule.
Our follow-up guide treats those responsibilities as questions, not instructions to alter treatment. The current Prometrium label also retains important warnings, including contraindications and dizziness or drowsiness concerns. A renowned institution does not remove those product-specific limits. The review supports Mayo as a documented clinical pathway while leaving product choice, suitability, cost and personal access to the actual care process.
Sources for this article
Source type matters. A provider page describes an offer; an exact product label describes that medicine.
- Mayo Clinic — Menopause and Women’s Sexual Health Clinic in MinnesotaOfficial health-system clinical service or location information; individual access, oral product and full price unconfirmed. · Checked 2026-09-29
- Mayo Clinic — Women’s Health Specialty Clinic in FloridaOfficial health-system clinical service or location information; individual access, oral product and full price unconfirmed. · Checked 2026-09-29
- DailyMed — Prometrium progesterone capsule, Acertis Pharmaceuticals LLCCurrent exact oral Prometrium DailyMed label, updated July 23, 2026; patient leaflet revision February 2026. Does not establish provider supply. · Checked 2026-09-29
- FDA — Understanding the Risks of Compounded DrugsFederal primary drug-label or regulatory information; applies only within the stated product and regulatory scope. · Checked 2026-09-29